The first blood and marrow transplant in Philippines was successfully performed in 1990, but despite this early start and the opening of two other transplant centers, only 21 transplants have been performed in two of the three existing transplant centers. The low number of transplants is due to several factors including the prohibitive cost.
Introduction
Blood and marrow transplantation or hematopoietic stem cell transplantation has emerged as a life-saving treatment for hematologic malignancies and other non-malignant disorders of the hematopoietic and immune system. Although blood and marrow transplantation has been practiced for several decades, it was first introduced in the country only in 1990 at the National Kidney and Transplant Institute. Our first patients included an 18-yearold male with severe aplastic anemia and a 20-year-old male with CML in chronic phase. Both patients engrafted successfully and were apparently doing well until the first patient succumbed to a severe fungal infection 12 months later and the second patient had a relapse of his leukemia 15 months after the transplant. Unfortunately, a fire gutted the area of the hospital, which was designated as the transplant unit, and it took several years before another one could be set up. In 1999, there was a renewed interest in blood and marrow transplantation when we received a referral to transplant a 2.5-month-old baby boy with SCID syndrome. This was also the first time a child was diagnosed with SCID syndrome in the country. The transplant proved to be a success with the child now 8 years of age and leading a normal life.
Country profile
The Philippines is an archipelago consisting of 7107 islands and has a total population of about 89.5 million. Half of the population is below 21 years of age and the dependency ratio is about 69.04%. The average household size is five persons and the per capita income is $5100. Thirteen percent of the total population of the country live in the national capital region where three hospitals with transplantation facility are located.
The blood and marrow transplant unit
The National Kidney and Transplant Institute used to have a one-bed stem cell transplant unit with HEPA filter. The St Luke's Medical Center maintains a two-room blood and marrow transplant unit located in a low-traffic area of the hospital. Features include positive pressure ventilation and high efficiency particulate air (HEPA) filtration. The water quality is maintained using reverse osmosis. Water and air quality is checked at regular intervals. A total of six nurses trained to care for the needs of transplant patients are made available whenever a transplant is performed. The core physician staff is composed of one adult hematologist, one adult hematologist-oncologist and one pediatric hematologist-oncologist. There is also a core of physicians from different subspecialties to support the blood and marrow transplantation team. St Luke's Medical Center is the first hospital in the Philippines to be accredited by the Joint Commission International and is affiliated with several hospitals in the United States.
Transplant experience
Despite the early start and the opening of two other blood and marrow transplantation centers, very few transplants have been performed with a total of only 21 transplants performed in two of the three transplant centers. Diseases for which blood and marrow transplantation has been performed by our team at the National Kidney and Transplant Institute, a government hospital and at the St Luke's Medical Center, which is a private institution, include the following: nine AML, four CML, two myelodysplastic syndrome (MDS), three severe aplastic anemia and one each of Fanconi anemia, primary amyloidosis and SCID syndrome. Eleven were male patients and 10 were female patients with age ranging from 2.5 months to 55 years. Of the AML patients, two patients were transplanted while in CR1, two in CR2, one in CR3 and the rest were all refractory cases. Two of the CML cases were transplanted in blastic phase, whereas the remaining two were transplanted in chronic phase. The MDS patients included one with refractory anemia with excess blast and one with refractory anemia with excess blast transformation (Table 1) .
Almost all transplants were HLA-identical sibling transplants except for two autologous (AML, amyloid) and two unrelated transplants (AML). The source of stem cells was bone marrow in 6 patients, peripheral blood in 14 patients and cord blood in 1 patient. There were three major and two minor ABO-mismatched transplants. Transplant was male to female in three cases and female to male in four cases out of the seven sex-mismatched transplants (Table 2) . Chimerism was determined using the Y-probe in the sexmismatched and the blood group for the ABO-mismatched transplants. For the others, short tandem repeat (STR) analysis was used to monitor engraftment and chimerism. The conditioning regimen used for leukemia and MDS was the standard dose BU and CY, whereas for aplastic anemia, we used the Seattle protocol using CY and anti-lymphocyte globulin. We did not give any conditioning for the SCID patient and we gave BU-CY-anti-thymocyte globulin for the unrelated transplants. One patient with amyloidosis was conditioned with 140 mg melphalan. GVHD prophylaxis consisted of CYA and MTX. The majority of the patients received low-molecular-weight heparin and ursodeoxycholic acid as prophylaxis for the sinusoidal obstruction syndrome (SOS). All patients received prophylaxis with ciprofloxacin, trimethoprim-sulfamethoxazole, acyclovir or valaciclovir and fluconazole (Table 3) .
Those who received bone marrow grafts received a mean total nucleated cell dose of 3.6 Â 10 8 /kg (range 3.2-4.0) whereas those who received PBSC received a mean CD34 dose of 7.11 Â 10 6 /kg (range 1.4-16.76). The umbilical cord blood CD34 dose was 2.6 Â 10 5 /kg. Engraftment with absolute neutrophil count of 4500 was achieved as early as day 9 in one patient and as late as day 23 in another patient. Four patients developed grade II-III acute GVHD, whereas six patients developed chronic GVHD (four extensive, two limited). Severe SOS was noted in three patients. Two patients recovered from SOS after treatment with high-dose methylprednisone and charcoal filtration. Three patients experienced hemorrhagic cystitis. All patients were positive for CMV before transplant. CMV antigenemia was observed in eight patients for which preemptive treatment with ganciclovir was given (Table 4) . Most infections were bacterial with Burkholderia cepacia and Klebsiella pneumonia being the most common agents. Cryptosporidial diarrhea occurred in one patient. One patient developed severe amoebic colitis concurrent with grade II gut GVHD. Pulmonary tuberculosis was present pretransplant in three patients, but worsening was not observed during and after the transplant. One patient had autoimmune hemolytic anemia following a major ABO-incompatible transplant.
There were three early transplant-related mortalities secondary to candida sepsis, severe SOS and multiorgan failure. One patient with Fanconi anemia died 2 years after blood and marrow transplantation due to late graft failure. Leukemic relapse was noted in eight patients. Seven patients are alive 12 months to 8 years after the transplant with a median of 51 months (range 11-94 months). These include two patients with AML in CR2 and one each of patients transplanted with SCID syndrome, AML in CR3, AML in CR1, MDS and severe aplastic anemia (Table 5) . 
Challenges to blood and marrow transplantation
There are many challenges to sustaining a blood and marrow transplantation program in our country. The cost of medical care, which entails intensive conditioning and aggressive supportive care, is not affordable by the majority of patients despite the fact that the cost of the blood and marrow transplantation is much less compared with many Western countries. Our first successful transplant in an 18-year-old male with severe aplastic anemia cost only $20 000 in 1990 and the cost of transplant for the SCID patient in 1999 was about $10 000. At present, the cost could range from $30 000 to $50 000 for an uncomplicated transplant in adult patient with AML. The cost of medicines is also one of the highest in Asia. Much of the cost of medical care is shouldered by the individual, as government subsidy from the national health insurance system is very minimal and not universally available. Other government agencies such as the Philippine Charity Sweepstakes Office give nominal financial aid to cover medical expenses. Non-governmental organizations would rather support other health programs that will benefit more people. At the same time, many patients are financially depleted by the time the transplant is planned. For the 10% of the population who can afford the procedure, the United States is the preferred place for the transplant mainly because of guarantees in terms of extensive experience in the field as well as the availability of a full range of medical and supportive care services. It also remains that despite the fact that transplantation has been successfully performed in the country, there is still lack of confidence in the overall capability of local transplant centers. The reasons include lack of widespread experience in blood and marrow transplantation compared with other countries, problems with adequate blood supply, lack of availability of medications for complications (that is, new agents for GVHD, new-generation anti-microbials, defibrotide for SOS, and so on). There is also a growing concern among patients regarding the overall quality of medical care in the Philippines as a result of the exodus of doctors and nurses and other health personnel out of the country. This has led to a lack of regular pool of nurses trained to care specifically for blood and marrow transplantation patients. At present, there are only 100 hematologists and 150 oncologists in this country of 90 million people. There are also very few physicians trained in blood and marrow transplantation at present and it has been difficult for us to find formal training for interested hematologists/oncologists. There is also a lack of awareness regarding the indications for blood and marrow transplantation, the most appropriate time to refer patients and the procedure to be done. Many patients are being referred late and after multiple relapses of the disease and have subsequently incurred organ toxicities from previous therapies.
Additional obstacle to transplantation is the lack of suitable donors for many patients. Although we have been successful in obtaining unrelated cord blood and PBSC from a Japanese Cord Blood Bank and from the Buddhist Tzu Chi Buddhist Stem Cell Center in Taiwan, there is a need for better networking with other countries.
Future directions in transplantation
Global influences on the future of blood and marrow transplantation in the Philippines include the discovery and availability of newer, less risky treatment for transplantable illnesses such as CML and ALL, and the continued rise in the cost of life-saving anti-neoplastic and immunosuppressive drugs essential in successful transplantation.
Local influences on the future of blood and marrow transplantation in the Philippines include not just the global influences stated above but also internal factors such as economic growth and improvement in the healthcare system. It is hoped that younger doctors and nurses trained and educated in transplantation in more experienced centers abroad will settle in our country and reverse the current brain drain we are experiencing. Better education and awareness among practicing doctors on the benefits of stem cell transplantation will go a long way in improving the referral system among practicing hematologists and oncologists, allowing this treatment option to reach those who will benefit most from it.
These are the challenges facing blood and marrow transplantation in the Philippines today. Its future will be determined by how these challenges are met and overcome not just by doctors but also by all stakeholders of this difficult but life-saving procedure.
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